Use of anti-vascular endothelial growth factor drugs for eye disease in Tuscany: Development and test of indicators of treatment intensity
- 30 October 2019
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 30 (6) , 1440-1447
Abstract
We aimed to develop indicators based on electronic administrative data to compare treatment intensity at a hospital level in Tuscany, Italy. Data from 3 university hospitals (UHs), 11 local hospitals (LHs) and 2 private hospitals were analysed. Patients newly treated with an intravitreal injection were followed up for 365 days. Indicator #1 concerned hospitals with >80% of injections linked to a drug and patients with all injections linked to a drug. Indicator #2 included patients who received ⩾3 injections during the first 90 days, regardless of injection-drug linkage. Indicator #1 was computed on four hospitals and included 3210 patients (48.3%). The average number of injections was 3.24 in the largest UH1. Compared to the latter, indicator #1 was significantly lower in UH2 and UH3 (−0.47 and −0.58, respectively; p < 0.001). Indicator #2 was computed on all hospitals and included 2789 patients (41.9%). UH1 delivered about 4.33 injections. Compared to the latter, LH4 delivered +0.62 injections (p < 0.001) and nine other hospitals delivered between −0.22 and −0.94 injections (p < 0.05). The two indicators proved to have the potential for supporting clinicians and policy makers in promoting the appropriate treatment intensity with intravitreal anti-vascular endothelial growth factor drugs.Keywords
This publication has 12 references indexed in Scilit:
- Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW studyBMJ Open Ophthalmology, 2019
- Healthcare Utilization and Treatment Patterns in Diabetic Macular Edema in Korea: a Retrospective Chart ReviewJournal of Korean Medical Science, 2019
- Treatment outcomes and predicting factors for diabetic macular edema treated with ranibizumab – One-year real-life results in TaiwanJournal of the Formosan Medical Association, 2019
- Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitorsProgress in Retinal and Eye Research, 2018
- Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)Clinical Ophthalmology, 2018
- Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future PossibilitiesPharmaceutics, 2018
- UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practiceBritish Journal of Ophthalmology, 2017
- METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2016
- Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA studyBritish Journal of Ophthalmology, 2016
- Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010American Journal of Ophthalmology, 2012